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Abstract: Although the use of wearable technology to characterize gait disorders in daily life is
increasing, there is no consensus on which specific gait bout length should be used to characterize
gait. Clinical trialists using daily life gait quality as study outcomes need to understand how gait bout
length affects the sensitivity and specificity of measures to discriminate pathological gait as well as
the reliability of gait measures across gait bout lengths. We investigated whether Parkinson’s disease
(PD) affects how gait characteristics change as bout length changes, and how gait bout length affects
the reliability and discriminative ability of gait measures to identify gait impairments in people with
PD compared to neurotypical Old Adults (OA). We recruited 29 people with PD and 20 neurotypical
OA of similar age for this study. Subjects wore 3 inertial sensors, one on each foot and one over
the lumbar spine all day, for 7 days. To investigate which gait bout lengths should be included to
extract gait measures, we determined the range of gait bout lengths available across all subjects.
To investigate if the effect of bout length on each gait measure is similar or not between subjects with
PD and OA, we used a growth curve analysis. For reliability and discriminative ability of each gait
measure as a function of gait bout length, we used the intraclass correlation coefficient (ICC) and area
under the curve (AUC), respectively. Ninety percent of subjects walked with a bout length of less
than 53 strides during the week, and the majority (>50%) of gait bouts consisted of less than 12 strides.
Although bout length affected all gait measures, the effects depended on the specific measure and
sometimes differed for PD versus OA. Specifically, people with PD did not increase/decrease cadence
and swing duration with bout length in the same way as OA. ICC and AUC characteristics tended
to be larger for shorter than longer gait bouts. Our findings suggest that PD interferes with the
scaling of cadence and swing duration with gait bout length. Whereas control subjects gradually
increased cadence and decreased swing duration as bout length increased, participants with PD
started with higher than normal cadence and shorter than normal stride duration for the smallest
bouts, and cadence and stride duration changed little as bout length increased, so differences between
PD and OA disappeared for the longer bout lengths. Gait measures extracted from shorter bouts are
more common, more reliable, and more discriminative, suggesting that shorter gait bouts should be
used to extract potential digital biomarkers for people with PD.
Keywords: mobility; Parkinson’s disease; bout length; wearable sensors; daily life
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1. Introduction
Gait impairments are the leading cause of falls and disability in people with Parkinson’s disease
(PD) [1–4]. Gait in people with PD is characterized by slow and short strides, shuffling, long
double-support time, large stride-to-stride variability, and small arm swing [4–6]. Hence, quantitative
gait assessment can be very useful for characterizing gait impairments [5], early detection of disease
onset [7], tracking the progression of the disease [7], and testing the efficacy of interventions [8].
Recently, the use of wearable technology has made it feasible to quantify gait quality outside the
laboratory during daily life [9–29]. Although the use of wearable technology is increasing in daily
life environments, this is still a relatively new field of research in which algorithms and data analysis
methods are under continuous development [11,20,21,30–34]. Furthermore, definitions about what is
considered a gait bout (i.e., a period of continuous walking) differ, making comparisons across studies
difficult [31,32,35–39].
It is also unclear what gait bout length to use to extract gait characteristics during daily life
activities [11,34]. For example, gait bout lengths ranging from three steps to longer than 60 s have been
used [11,25,34,40–42]. The advantage of shorter bouts is that the majority of walking during daily life
occurs in shorter gait bouts, so gait measures can be averaged across more bouts [11,36,43]. However,
many studies evaluating daily life gait quality characteristics have limited analysis to gait bouts longer
than 10 s [41,44], 30 s only [34], 60 s only [11,21,45], or have used all gait bout lengths together [40,41].
The advantage of characterizing gait during longer bouts is that it focuses on what laboratory gait
studies have called “steady-state gait” that is not affected by turns, gait initiation, gait termination,
and hesitations that necessarily impact gait characteristics.
A few studies have shown that gait characteristics change as gait bout length increases [11,46–48].
Researchers and clinical trialists using daily life gait quality as study outcomes need to understand
how gait bout length affects the sensitivity and specificity of measures to discriminate pathological gait,
as well as the reliability of gait measures across gait bout length. It is possible that pathologies, like PD,
that affect neural control of gait also affect how gait characteristics change as bout length changes.
As PD impairs the ability to initiate and terminate muscle activity, even though peak and sustained
muscle activity can eventually reach normal levels, we hypothesized that scaling of some specific
gait measures may be impaired in PD. Thus, gait differences between PD and neurotypical subjects
with similar age (Old Adults, OA) may be larger for short gait bouts because a greater percentage of
time involved initiating and terminating muscle activity than for long gait bouts [49–51]. As a result,
the discriminative ability of gait measures to separate PD from OA would be expected to be greater
with shorter bout lengths. In addition, since more shorter than longer bout lengths are available for
analysis during daily living, gait measures may also be more reliable for short than long gait bouts.
The aims of the study were to investigate: (1) the distribution and range of gait bout lengths
available for analysis across a week of monitoring, (2) how gait bout length affects gait measures,
and (3) how gait bout length affects reliability and discriminative ability of gait measures in people
with PD and OA. We hypothesized that PD would affect the scaling of some gait measures with gait
bout length and that shorter gait bout lengths (in contrast to larger gait bout length suggested in
Reference [11]) should be used to extract gait measures in daily life for people with PD because of the
better discriminative ability and reliability than longer gait bouts.
2. Methods
2.1. Participants
Twenty-nine people with idiopathic PD and 20 neurotypical adults of similar age participated
in the study. Inclusion criteria for PD were a diagnosis of idiopathic Parkinson’s disease by a
movement disorders neurologist with the United Kingdom Parkinson’s disease Society Brain Bank
criteria, Hoehn and Yahr scores of II–IV, and complaints about gait disturbances. PD severity was
assessed by a trained examiner using the Movement Disorders Society-Unified Parkinson’s Disease
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Rating Scale (MDS-UPDRS) [52]). Exclusion criteria for all subjects included the inability to follow
protocol instructions, other factors affecting gait such as musculoskeletal disorders, uncorrected
vision, or vestibular problems, or inability to stand or walk in the home without an assistive device.
The experimental protocol was approved by the Institutional Review Board of the Oregon Health &
Science University. All the participants provided informed written consent.
2.2. Daily Life Gait Data Collection
Subjects were asked to wear three inertial sensors (Opals by APDM, Inc., Portland, OR, USA): one
on top of each foot, and one over the lower lumbar area with an elastic belt for a week of daily activities,
for at least 8 h/day. The sampling rate of Opals was 128 Hz. The subjects removed the sensors at night
to recharge the batteries. Data were stored in the internal memory of the Opals. After completion of a
week of data collection, subjects returned sensors either by mail using a pre-paid box or to a research
assistant study coordinator, who met the subject at their home. Data were then uploaded to a secure
cloud-based database and downloaded to a local computer for further processing.
2.3. Measures of Gait
The gait algorithms used for extracting spatial and temporal measures were described
previously [20,22], and were identical to that of Mobility Lab (APDM Wearable Technologies, Portland,
Oregon), after the identification of gait bouts and turns [53–55]. Briefly, the algorithm first searches
for possible bouts of gait from the feet data and for turns based on rotational orientation about the
vertical axis of the pelvis. Second, individual steps were combined into potential bouts of gait, as long
as the duration from one step to the next step is no longer than 2.5 s. Finally, each possible bout that
contains at least 3 steps and is at least 3 s in duration is processed with the commercial gait analysis
algorithms included in APDM Mobility Lab. The gait measures used for this analysis were gait speed,
stride length, cadence, double-support, swing duration, and pitch of feet at initial ground contact.
We purposefully chose not to use the coefficient of variation measures as the number of strides in the
majority of bouts was less than the minimum number of strides required to accurately calculate a
coefficient of variation (20 strides) [56,57].
We define gait bout length in terms of the number of strides in the bout because it helps to
eliminate the differential effects of gait speed and stride length between groups on the gait bout length.
Other studies have used gait bout duration [11,34,46], the distance traveled during a particular walk
test [58], and the number of strides in a bout [42,47] as gait bout length measures.
2.4. Statistical Analysis
The Shapiro–Wilk test was used to assess the normality of variables. Since not all variables were
normally distributed, a non-parametric test (specifically, Mann–Whitney U tests) was used throughout
to investigate differences between PD and OA groups.
To investigate what bout length could be used to extract gait measures between groups,
we investigated the range of gait bout lengths that are present in most of the PD and OA subjects.
Specifically, we divided weekly gait bout lengths into 40 bins with empirical bin sizes of 5 strides,
starting from 3 strides in a bout (e.g., 3–7, 8–12, 13–17, . . . , 203–207 bins) and calculated the percentage
of subjects walking as a function of bout length for each group during a week of recording. We also
calculated the percentage of bouts available as a function of bout length in each group. Bouts greater
than 207 strides were discarded as only a very small percentage (0.9%) of gait bouts above this length
were available across all the subjects during a week of daily recording.
To investigate the effect of bout length on gait measures, we restricted the rest of the analysis to
bout bins in which at least 90% of subjects walked in both groups (i.e., OA and PD). We first visually
compared how the gait metrics changed with bout length for the PD and OA groups, by plotting the
mean and standard error of each gait metric as a function of the bout length. To statistically compare
the effects of bout length on gait measures between the PD and the OA groups, we used growth curve
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analysis [59]. The overall curve for each gait measure was modeled with second-order (quadratic)
orthogonal polynomials and fixed effects of group on all bin sizes for the gait bout length (for the growth
model example, see Equations (1) and (2)). The OA group was treated as the baseline, and parameters
were estimated for the PD group. The model also included random effects of participants on each bout
length bin size. The fixed effects of the group (PD and OA) were added individually, and their effects on
model fit were evaluated using the likelihood ratio test for model comparisons. Specifically, we started
the analysis with a base model (model 1) that just has the Level 1 structure and the random effects,
without any effects of group, then we added the fixed effect of group on the intercept (model 2), linear
(model 3) term/component of the bout length, and finally, the full model with effects of group on all
terms/components (i.e., intercept, linear, and quadratic) of the bout length (model 4). Improvements in
model fit were evaluated using −2 times the change in log-likelihood, which is distributed as chi-square
(χ2) with degrees of freedom equal to the number of parameters added.
Examples of the growth curve model for each gait measure are as follows:
Level 1 : Yi j = β0i + (β1i ∗X j) + (β2i ∗X j2) + εi j (1)
Level 2 :

β0i = γ00 + (γ0Group ∗Group) + ϕ0i
β1i = γ10 + (γ1Group ∗Group) + ϕ1i
β2i = γ20 + (γ2Group ∗Group) + ϕ2i
(2)
where, β0i is the intercept, β1i is the linear slope, and β2i is the rate of change of the quadratic curvature.
Y is gait measure (example, gait speed), and X is a quadratic orthogonal polynomial of bout length
bins. The fixed effects γ0Group, γ1Group, and γ2Group capture the systematic differences between groups
(example, OA versus PD). The random effects ϕ0i, ϕ1i, and ϕ2i capture (random) individual variability
among participants.
To investigate the inter-day reliability of each gait measure and for each bout size bin, we used
the intraclass correlation coefficient (ICC) [60] for daily averages. We only included days that had at
least 3 values for each bout size range. To investigate the discriminative ability of each gait measure,
we computed the receiving operating characteristics (ROC) curve and calculated the area under the
curve (AUC) [61]. All statistical analyses were performed using R version 3.0.2, and Python version
3.6 software. The statistical significance was set to p < 0.05.
3. Results
3.1. Group Characteristics and Adherence
Participants with PD were mildly to moderately affected: MDS-UPDRS Part III score in the ON
medication state: 34.66 ± 11.02, and Hoehn and Yahr stage: 2.07 ± 0.45 with I (n = 1), II (26), III (1),
and IV (1). Table 1 shows the demographics of subjects who participated in this study. Age, height,
and weight were similar between the PD and OA group. Adherence to the weekly recordings averaged
67.66 ± 12.53 h for the PD group and 64.67 ± 10.13 h for the OA group.
Table 1. Demographics and activity characteristics of each group.
OA (N = 20) PD (N = 29) p
Mean SD Mean SD
Age (years) 66.85 7.16 67.66 5.27 0.45
Height (m) 1.70 0.18 1.71 0.13 0.32
Weight (kg) 74.61 9.38 75.95 12.74 0.91
Male/Female (#) 12/8 17/12
Bouts/hour (#) 22.37 1.95 20.72 1.30 0.68
Turns/hour (#) 102.89 10.96 77.67 7.59 0.03
OA = Old Adults; PD = Parkinson’s disease; SD = standard deviation.
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3.2. Frequency of Gait Bout Lengths over a Week of Daily Life
The majority of participants in both groups walked with gait bouts of less than 53 strides per bout
across the 7 days (Figure 1). Specifically, 90% of the OA group had less than 53–57 strides per bout,
with the number of subjects dropping to 80% for less than 58–62 strides per bout. Similarly, 90% of the
PD group had less than 53–57 strides per bout, with the number of subjects dropping to 86% for less
than 58–62 strides per bout. Figure 1A shows the percentage of subjects (who had one or more bouts in
a specific bin of bout length across the 7 days) as a function of gait bout length recorded in each group.
Based on the above results, we chose to restrict the analysis to bouts with less than 53 strides for the
rest of the analysis.
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Figure 1. (A) Percentage of subjects alking as a function of bout length, and (B) percentage of all
bouts perfor ed by each participant.
The majority of gait bouts (>50%) were very short bouts (less than 12 strides per bout) in 60%
of PD and 52% in OA groups. The percentage of gait bouts follow a decreasing trend in each group
as bout length increases. Further, the PD group had a larger percentage of bouts in the shortest bout
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(3–7 strides) length, compared to the OA group (35% versus 28%, respectively). Figure 1B shows the
percentage of gait bouts available as a function of bout length in each group.
3.3. Gait Measures as a Function of Gait Bout Length
Gait speed, stride length, and foot pitch at initial contact increased, and double-support time
decreased with increasing gait bout length in both the OA and PD groups. These gait measures
appeared to change similarly with bout length for both groups. However, unlike these four gait metrics,
cadence and swing duration did not scale with bout length for the PD group, whereas the OA group
did scale with bout length (Figure 2).
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The PD group significantly differed from the OA group in both the slope and rate of change (but
not the intercept) of cadence and swing duration with bout length. None of the other gait measures (i.e.,
gait speed, stride length, the pitch of foot at initial contact, and double-support time) showed the same
effect as that of cadence and swing duration, as shown in Table 2. Specifically, for cadence, the effect of
the group on the intercept (i.e., model 1 to model 2) did not improve model fit (χ2 (1) = 1.132; p = 0.287),
however, the effect of the group on the linear (i.e., model 2 to model 3) and quadratic (i.e., model
3 to model 4) terms improved the model fit (χ2 (1) = 5.091; p = 0.024, and χ2 (1) = 9.081; p = 0.003,
respectively), indicating that the OA and PD groups differed in the slope and rate of change of cadence.
Similarly, for swing duration, the effect of the group on the intercept did not improve model fit (χ2
(1) = 1.677; p = 0.195); however, the effect of the group on the linear (χ2 (1) = 7.294; p = 0.007) and
quadratic terms did improve model fit (χ2 (1) = 15.547; p = 0.000), indicating that the OA and PD groups
differed in the slope and rate of change of swing duration. The details of the fixed effect parameter
estimates, and their standard error along with p-values estimated using the normal approximation
for the t-values, are summarized in Appendix A, Table A1. The growth curve model fit for each gait
measure is shown in Figures 3 and 4.
Table 2. Results of growth curve analysis with second-order (quadratic) orthogonal polynomial of bout
length with the fixed effect of group (OA and PD) for each gait measure.






Intercept 418.596 11.015 0.001
Linear 419.489 1.785 0.182
Quadratic 423.150 7.323 0.007
Stride Length (meters)
Intercept 432.732 13.695 <0.001
Linear 436.061 6.656 0.010
Quadratic 438.011 3.901 0.048
Pitch at Initial Contact
(degrees)
Intercept −1184.259 14.521 <0.001
Linear −1180.753 7.012 0.008
Quadratic −1178.601 4.304 0.038
Double Support (%)
Intercept −1061.506 0.975 0.324
Linear −1059.899 3.214 0.073
Quadratic −1059.399 0.999 0.317
Cadence (strides/minute)
Intercept −1106.360 1.132 0.287
Linear −1103.814 5.091 0.024
Quadratic −1099.274 9.081 0.003
Swing Duration
(seconds)
Intercept 1206.537 1.677 0.195
Linear 1210.184 7.294 0.007
Quadratic 1217.958 15.547 <0.001
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Figure 5. The intraclass correlation coefficient (ICC) versus area under the curve (AUC) of (A) Gait
speed, (B) Stride length, (C) Pitch at initial contact, (D) Double support, (E) Cadence, and (F) swing
duration for various bout lengths. The total percentage of participants are shown inside the bracket of
bout length bins.
4. Discussion
Most gait bouts are quite short during daily life. In fact, our study showed that 60% of gait bouts
in PD and 52% of gait bouts in OA consist of very short bouts (3–12 strides), and at least 75% of bouts
were less than 22 strides (76% in OA and 83% in PD). Very short gait bouts in daily life agree with the
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results of previous studies showing that 55% of gait bouts in OA and 59% of gait bouts in PD were less
than 10 s [11]. Another study in young neurotypical adults found that 40% of gait bouts were less than
6 strides, and 75% of gait bouts were less than 20 strides [36]. Likewise, 50% of gait bouts were less
than 10 strides in the frail elderly [47], 50% of bouts were less than 13 s [43], and at least 50% of bouts
were less than 8 s in both faller and non-faller groups [62]. Such a preponderance of short walking
bouts in daily life likely reflects natural mobility to accomplish daily tasks as well as natural mobility
during daily activities and moving in constrained environments, such as a house.
Gait speed and stride length scaled up with increased gait bout length for both the OA and
PD groups. This result agrees with a previous study in PD and OA groups [11]. Since the inertial
sensors were on the feet, we also observed that the foot pitch angle was more dorsiflexed the longer
the bouts (and faster gait with longer steps). Not surprisingly, as gait speed increased with bout length,
double-support time decreased [63]. Thus, PD does not interfere with the scaling up of the pace of gait
as bout length increases.
Unlike these pace measures, the temporal gait measures of cadence (strides per minute) and swing
time duration scaled differently with longer bout lengths in the PD group alone. The result of the
lack of change in cadence across bout lengths for PD, but significant changes for OA, is that cadence
was higher than OA in shorter bouts but within the normal range for longer bouts. Similarly, the PD
group swing time was shorter than OA for shorter bouts but within the normal range at longer bouts.
Thus, differences between groups were most prominent for shorter bouts but were absent with longer
bout length.
Swing duration showed a similar trend to not scale up with gait bout length in the PD group,
unlike the OA group that had shorter swing durations the longer (and faster) subjects walked.
Swing duration in the PD group was shorter than OA for the shortest gait bouts (3–7 strides) but then
tended to be longer than normal as gait bouts lengthened, primarily because healthy OA subjects
quickly shortened swing duration as bout length (and therefore gait speed) increased. The inability to
change cadence with bout length likely resulted in unchanged swing duration.
It is unclear why cadence is higher than normal for shorter bout lengths and did not increase
with bout length in the PD group. Similar to our results, a previous study also showed that increasing
treadmill speed resulted in an increase in both cadence and stride length in the OA group but only
stride length in a PD group [64]. High cadence has been associated with PD previously and thought
to represent partial compensation for short stride length due to weak (bradykinetic) plantar flexion
torques that should propel subjects forward for gait [64].
Inability to scale up temporal vigor of gait (steps per minute with faster swings) when intending a
longer walk may be unique to PD and reflected in their bradykinetic gait. Scaling up the vigor of motor
output has been attributed to control by the basal ganglia [51]. The loss of dopamine neurotransmitter
results in reduced basal ganglia output to other motor centers, including the thalamus to motor cortex,
the brainstem, and cerebellar locomotor centers [3]. People with PD have previously been shown
to lack scaling up postural forces in responses to longer, more destabilizing surface translations like
younger and older neurotypical adults [65].
Our ICC and AUC results suggested that the shorter bouts yield the most reliable and discriminative
gait measures to characterize parkinsonian gait compared to age-matched controls. It is unclear why
bout-to-bout reliability was better for shorter bouts than for longer bouts, especially for cadence and
double-support time. There was a disparity in the number of gait bouts between shorter vs. longer gait
bouts, but that should not necessarily result in better ICCs for shorter bouts. Perhaps longer gait bouts,
associated with prescribed aerobic exercise as subjects walked around outdoors, resulted in a greater
variety of voluntary (less automatic) gait temporal features than shorter gait bouts. Shorter bouts
are also less likely interrupted by turns and obstacles that would alter temporal components of gait
compared to longer bouts. Nevertheless, the goal to measure what has been called in laboratories as
“steady-state gait” without effects of gait initiation, gait termination, turns, and other transitions may
not be a feasible or desirable goal when measuring gait characteristics in natural daily-life activities.
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Our AUC results are inconsistent with a previous study in which the authors found that gait
bout length between 30 and 60 s to gait bout length > 120 s showed more discriminative power
to discriminate people with PD from age-matched healthy control subjects than short bouts [11].
Also, the authors found that none of the gait measures discriminated gait characteristics in people
with PD from healthy age-matched control subjects for very short bouts (gait bout length < 10 s).
This inconsistency in the results may be partly due to the extensive validation criteria we use to ensure
that the periods of gait analyzed are during periods of steady-state gait and straight progression.
The earlier study used accelerometers placed on the lower back to detect strides with a different
methodology. In particular, our analysis excluded gait during turns, which cannot be detected reliably
without the use of both an accelerometer and a gyroscope. This is the first study providing evidence
for the importance of shorter bouts as a robust marker of PD gait.
There are several limitations to the current study. First, we had a modest sample size. Future work
with larger cohorts is needed to investigate if these findings would generalize. Second, our shorter
and more reliable gait bouts may be in line with the moderate to long gait bouts detected with
accelerometers on the lower back [11], because we require at least two consecutive left-right-left-right
steps, and excludes step initiation or turns that may be included in the gait bouts detected with lower
back accelerometry. Third, we had three sensors (two on the feet and one over the lumbar), and we
asked participants to charge sensors at night while other approaches have only one sensor incorporating
accelerometer at the lumbar for a week of recording. Finally, we did not consider the effect of gait speed
and motor fluctuations while exploring the effect of gait bout length on gait measures. It is possible that
people with PD walk faster and take longer gait bouts in the ON medication state. Hence, future work
should also explore the effect of bout length, with gait speed and medication state as covariates.
5. Conclusions
Our findings show the potential of focusing gait analysis on the shortest walking bouts in daily
life to develop digital biomarkers for people with PD. Swing duration during short walking bouts
over 7 days of monitoring provided the most sensitive and specific, and most reliable gait measure of
parkinsonian gait. The inability of people with PD to scale up some of their temporal characteristics of
gait with an increase of gait bout length may be unique to this particular type of neurological disease
and requires further study.
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Appendix A
Table A1. Parameter estimates for growth curve analysis of effect of group on gait measures in OA and
PD groups.
Gait Measure Term/Component ofBout Length Estimates Std. Error t p
Gait Speed
(meters/second)
Intercept 0.892 0.025 35.549 0.000
Linear 0.271 0.028 9.629 0.000
Quadratic −0.089 0.024 −3.701 0.000
PD: Intercept −0.128 0.033 −3.916 0.000
PD: Linear 0.058 0.037 1.570 0.116
PD: Quadratic 0.088 0.031 2.808 0.005
Stride Length
(meters)
Intercept 1.056 0.031 34.286 0.000
Linear 0.237 0.026 9.111 0.000
Quadratic −0.059 0.023 −2.559 0.010
PD: Intercept −0.166 0.040 −4.144 0.000
PD: Linear 0.095 0.034 2.790 0.005




Intercept −19.025 0.958 −19.857 0.000
Linear −5.829 0.909 −6.412 0.000
Quadratic 1.915 0.743 2.577 0.010
PD: Intercept 5.157 1.246 4.140 0.000
PD: Linear −3.744 1.189 −3.148 0.002
PD: Quadratic −2.059 0.974 −2.115 0.034
Double
Support (%)
Intercept 24.097 0.651 37.002 0.000
Linear −4.585 0.478 −9.586 0.000
Quadratic 1.969 0.563 3.500 0.000
PD: Intercept 1.441 0.847 1.702 0.089
PD: Linear −1.046 0.626 −1.670 0.095
PD: Quadratic −0.739 0.735 −1.006 0.314
Cadence
(strides/minute)
Intercept 49.988 0.914 54.719 0.000
Linear 4.596 0.927 4.959 0.000
Quadratic −2.882 0.577 −4.994 0.000
PD: Intercept 1.440 1.188 1.212 0.225
PD: Linear −2.608 1.209 −2.158 0.031
PD: Quadratic 2.412 0.756 3.191 0.001
Swing Duration
(seconds)
Intercept 0.467 0.007 62.463 0.000
Linear −0.022 0.008 −2.966 0.003
Quadratic 0.016 0.004 4.205 0.000
PD: Intercept −0.020 0.010 −2.039 0.041
PD: Linear 0.027 0.010 2.706 0.007
PD: Quadratic −0.022 0.005 −4.387 0.000
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